AGBA Acquisition Ltd. (AGBAU), announced the pricing of their $40 million SPAC IPO this morning and the units are expected to begin trading today under the symbol Nasdaq: AGBAU.
AGBA Acquisition Ltd, which will be focusing on businesses in China, will be led by Gordon Lee, as Chief Executive Officer, and Vera Tan, as Chief Financial Officer.
Total SPAC deal count for 2019 year-to-date is now 22 with $4.904 billion in gross proceeds raised. The offering is expected to close on or about May 16th, 2019.
Congratulations to all.
Maxim Group LLC acted as sole book-running manager.
Loeb & Loeb LLP and Hunter Taubman Fischer & Li LLC, were Issuer’s Counsel and Underwriter’s Counsel, respectively.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...